Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41062288/
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of early onset atherosclerosis. Evinacumab, an angiopoietin-like protein 3...
This case report shows evinacumab significantly improved lipid profiles and atherosclerosis-related markers in homozygous familial hypercholesterolemia, suggesting broader cardiovascular benefits beyond LDL-cholesterol reduction in refractory disease management.
Share
Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41423223/
Atherosclerotic cardiovascular disease (ASCVD) is associated with a very high risk of secondary cardiovascular events. Elevated low-density lipoprotein cholesterol (LDL-C) is a major determinant in the progression of ASCVD and...
Aggressive LDL-C reduction is central to secondary ASCVD prevention. Statins, with ezetimibe or PCSK9 inhibitors, lower risk significantly, supporting stricter guideline-recommended LDL-C targets across coronary, cerebrovascular, and peripheral artery disease.
Share
The association between triglyceride-glucose index and all-cause/cardiovascular mortality in patients with different glucose metabolism statuses - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40993712/
TyG was associated with an increased risk of all-cause and cardiovascular death in the normoglycemic subgroup, but not in the dysglycemic subgroup. In the diabetes subgroup, the association between the...
Study shows triglyceride-glucose index predicts mortality differently by metabolic status—linear risk increase in normoglycemia, U-shaped association in diabetes, none in dysglycemia—highlighting TyG as a useful, context-dependent prognostic marker.
Share
A practical guide to the management of dyslipidaemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41504909/
Dyslipidaemia, especially elevated low-density lipoprotein cholesterol (LDL-C), is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Dyslipidaemia remains underdiagnosed and undertreated. Dyslipidemia is highly prevalent in Germany. Even...
Dyslipidaemia, driven by elevated LDL-C and other lipids, increases ASCVD risk; management includes lifestyle changes, statins, and combination therapies, with emphasis on early diagnosis, risk modifiers, and achieving treatment targets.
Share
The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41727206/
Supplementing with MLT in CKD can gently raise HDL-C levels, decrease oxidative stress, and improve sleep quality. While these effects are encouraging, more extensive and carefully planned clinical trials are...
Meta-analysis of RCTs shows melatonin in CKD modestly increases HDL, reduces oxidative stress, and improves sleep, with no significant effects on other lipids or inflammation; larger trials needed for confirmation.
Share